110 related articles for article (PubMed ID: 2225856)
21. Effect of the novel orally active angiotensin converting enzyme inhibitor alacepril on cardiovascular system in experimental animals.
Takeyama K; Minato H; Nakatsuji K; Suzuki H; Nose I; Oka M; Hosoki K; Hatano N; Kadokawa T
Arzneimittelforschung; 1986; 36(1):69-73. PubMed ID: 3513779
[TBL] [Abstract][Full Text] [Related]
22. Effect of prolonged transit on measuring relative renal function.
Greenberg ID; Peterdy AE
AJR Am J Roentgenol; 1987 Oct; 149(4):860-1. PubMed ID: 3498346
[No Abstract] [Full Text] [Related]
23. Direct renal action of captopril (SQ 14225): dissociation of natriuretic and vascular actions in isolated perfused rat kidney.
Ogihara T; Yasui T; Nakane H; Nakane Y; Satura T
Am J Cardiol; 1982 Apr; 49(6):1511-2. PubMed ID: 7041588
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of captopril on kidney function in various forms of hypertension.
Vetter W; Wehling M; Foerster EC; Kuhlmann U; Boerlin HJ; Greminger P; Vetter H
Klin Wochenschr; 1984 Aug; 62(15):731-7. PubMed ID: 6387263
[TBL] [Abstract][Full Text] [Related]
25. The value of captopril renal scintigraphy in assessing the results of percutaneous transluminal renal angioplasty and in following up renovascular hypertension--a case report.
Eren N; Unal S; Nişanci Y; Adalet K; Deligönül U; Meriç M
Angiology; 1994 Jan; 45(1):71-5. PubMed ID: 8285389
[TBL] [Abstract][Full Text] [Related]
26. Enhanced interaction between renovascular alpha(2)-adrenoceptors and angiotensin II receptors in genetic hypertension.
Jackson EK; Herzer WA; Kost CK; Vyas SJ
Hypertension; 2001 Sep; 38(3):353-60. PubMed ID: 11566904
[TBL] [Abstract][Full Text] [Related]
27. [The kallikrein-kinin system in renovascular hypertension].
Kushiro T
Nihon Jinzo Gakkai Shi; 1984 Jun; 26(6):823-9. PubMed ID: 6392636
[No Abstract] [Full Text] [Related]
28. Clinical evaluation of renovascular hypertension and therapeutic decisions.
Vaughan ED; Case DB; Pickering TG; Sosa RE; Sos TA; Laragh JH
Urol Clin North Am; 1984 Aug; 11(3):393-407. PubMed ID: 6205495
[TBL] [Abstract][Full Text] [Related]
29. Responsiveness to pressor agents in experimental renovascular and steroid hypertension. Effects of converting enzyme inhibitor and nephrectomy.
Marks ES; Bing RF; Thurston H; Russell GI; Swales JD
Hypertension; 1982; 4(2):238-44. PubMed ID: 6279494
[No Abstract] [Full Text] [Related]
30. Captopril suppresses glomerular filtration rate but not blood flow in the affected kidney in renovascular hypertension: report and comments on one case.
Fommei E; Ghione S; Palla L; Giaconi S; Marraccini P; Palombo C; Rosa C; Gazzetti P; Donato L
J Nucl Med Allied Sci; 1985; 29(1-2):175-7. PubMed ID: 3897484
[No Abstract] [Full Text] [Related]
31. Hypertension in paediatrics: can pre- and post-captopril technetium-99m dimercaptosuccinic acid renal scans exclude renovascular disease?
Minty I; Lythgoe MF; Gordon I
Eur J Nucl Med; 1993 Aug; 20(8):699-702. PubMed ID: 8404957
[TBL] [Abstract][Full Text] [Related]
32. Study of renovascular hypertension in rat. II. Effects of converting enzyme inhibitor (captopril) in the acute and chronic stages of two-kidney one-clip Goldblatt hypertension in rat.
Matsushita K
Tokai J Exp Clin Med; 1985 Apr; 10(1):31-6. PubMed ID: 3913058
[TBL] [Abstract][Full Text] [Related]
33. Renovascular hypertension due to Takayasu's arteritis demonstrated by Tc-99m ethylenedicysteine captopril scintigraphy.
Uğur O; Peksoy I; Caner B; Cekirge S; Balkanci F; Bekdik C
Clin Nucl Med; 1996 Sep; 21(9):714-6. PubMed ID: 8879872
[TBL] [Abstract][Full Text] [Related]
34. The value of the captopril test and the effect of captopril on renal function.
Lu ZW; Liu LS
J Hum Hypertens; 1990 Apr; 4(2):138-40. PubMed ID: 2187090
[TBL] [Abstract][Full Text] [Related]
35. Uptake of 99mTc(5+)-complexes in ischemic myocardial slices and their dissociable ability.
Li SL; Yan XX; Liu XY
Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):465-7. PubMed ID: 10322944
[TBL] [Abstract][Full Text] [Related]
36. Hypertension after renal transplantation: cyclosporine increases the diagnostic and therapeutic considerations.
Curtis JJ
Am J Kidney Dis; 1989 Jun; 13(6 Suppl 1):28-32. PubMed ID: 2660549
[No Abstract] [Full Text] [Related]
37. Comparison of scintigraphic renal differentials using radiolabeled orthoiodohippurate and glucoheptonate.
Jacobson AF; Matsuoka DT; Ferency GF; Miura RS; Avrin SA
Clin Nucl Med; 1991 Jun; 16(6):389-93. PubMed ID: 1868647
[TBL] [Abstract][Full Text] [Related]
38. Technetium-99m-ethylenedicysteine in the diagnosis and follow-up of renovascular hypertension.
Uğur O; Caner B; Cekirge S; Balkanci F; Ergün EL; Kostakoğlu L; Aras T; Bekdik C
Invest Radiol; 1996 Jun; 31(6):378-81. PubMed ID: 8761872
[TBL] [Abstract][Full Text] [Related]
39. The captopril challenge for renovascular hypertension.
Kaplan NM
Am J Hypertens; 1990 Jul; 3(7):588-90. PubMed ID: 2194513
[No Abstract] [Full Text] [Related]
40. Ceranapril (SQ 29,852), an orally active inhibitor of angiotensin converting enzyme (ACE).
DeForrest JM; Waldron TL; Harvey C; Scalese R; Hammerstone S; Powell JR; Karanewsky D
J Cardiovasc Pharmacol; 1990 Jul; 16(1):121-7. PubMed ID: 1696654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
